Grufity logo
Grufity logo

Latest Rhenman & Partners Asset Management AB Stock Portfolio

$810Million | No. of Holdings #86

Rhenman & Partners Asset Management AB Performance

2026 Q1-6.14%
YTD-6.14%
2025+14.42%

About Rhenman & Partners Asset Management AB and 13F Hedge Fund Stock Holdings

On 2026-05-14, the fund reported it's updated stock portfolio. In the 13F Holdings report, Rhenman & Partners Asset Management AB reported an equity portfolio of $810.5 Millions as of 31 Mar, 2026. <br><br> The top stock holdings of Rhenman & Partners Asset Management AB are BSX, REGN, LLY. The fund has invested 4.8% of it's portfolio in BOSTON SCIENTIFIC CORP and 4.6% of portfolio in REGENERON PHARMACEUTICALS. <br><br> The fund managers got completely rid off VERA THERAPEUTICS INC (VERA), PENUMBRA INC (PEN) and APELLIS PHARMACEUTICALS INC (APLS) stocks. They significantly reduced their stock positions in ALIGN TECHNOLOGY INC (ALGN), COOPER COS INC (COO) and DANAHER CORPORATION (DHR). Rhenman & Partners Asset Management AB opened new stock positions in STRYKER CORPORATION (SYK), VEEVA SYS INC (VEEV) and ABBOTT LABORATORIES (ABT). The fund showed a lot of confidence in some stocks as they added substantially to ALPHATEC HLDGS INC (ATEC), OSCAR HEALTH INC (OSCR) and ELEVANCE HEALTH INC (ANTX).
Rhenman & Partners Asset Management AB Equity Portfolio Value
Last Reported on: 14 May, 2026
$810Million
  as of May 14, 2026

Rhenman & Partners Asset Management AB Annual Return Estimates Vs S&P 500

Our best estimate is that Rhenman & Partners Asset Management AB made a return of -6.14% in the last quarter. In trailing 12 months, it's portfolio return was 7.25%.
  • Performance
  • S&P 500

New Buys

Ticker$ Bought
stryker corporation15,706,600
veeva sys inc14,983,800
abbott laboratories11,499,000
waystar hldg corp8,259,270
apogee therapeutics inc6,312,750
cardinal health inc5,705,370
nektar therapeutics4,245,050
sionna therapeutics inc3,507,880
New stocks bought by Rhenman & Partners Asset Management AB

Additions

Ticker% Inc.
alphatec hldgs inc250
oscar health inc153
elevance health inc115
iqvia hldgs inc100
denali therapeutics inc99.00
viking therapeutics inc92.77
steris plc91.67
stevanato group s p a86.82
Additions to existing portfolio by Rhenman & Partners Asset Management AB

Reductions

Ticker% Reduced
align technology inc-92.42
cooper cos inc-84.73
danaher corporation-81.78
xenon pharmaceuticals inc-79.86
the cigna group-79.3
insulet corp-77.05
brightspring health svcs inc-74.75
medtronic plc-69.59
Rhenman & Partners Asset Management AB reduced stake in above stock

Sold off

Ticker$ Sold
vera therapeutics inc-21,268,800
apellis pharmaceuticals inc-9,406,180
janux therapeutics inc-3,110,200
xencor inc-2,537,630
bruker corp-6,940,010
arcellx inc-8,704,200
privia health group inc-2,963,750
centessa pharmaceuticals plc-2,501,000
Rhenman & Partners Asset Management AB got rid off the above stocks

Sector Distribution

Rhenman & Partners Asset Management AB has about 90.8% of it's holdings in Healthcare sector.

  • Healthcare
  • Others
Sector%
Healthcare90.8
Others9.2

Market Cap. Distribution

Rhenman & Partners Asset Management AB has about 67.4% of it's portfolio invested in the large-cap and mega-cap stocks.

  • LARGE-CAP
  • MID-CAP
  • SMALL-CAP
  • MEGA-CAP
  • UNALLOCATED
  • NANO-CAP
Category%
LARGE-CAP60.1
MID-CAP15.9
SMALL-CAP8.4
MEGA-CAP7.3
UNALLOCATED7.2
NANO-CAP1.2

Stocks belong to which Index?

About 73.9% of the stocks held by Rhenman & Partners Asset Management AB either belong to S&P 500 or RUSSELL 2000 index.

  • S&P 500
  • RUSSELL 2000
  • Others
Index%
S&P 50045.1
RUSSELL 200028.8
Others26.2
Top 5 Winners (%)%
dianthus therapeutics inc
94.7 %
MLTX
moonlake immunotherapeutics
34.3 %
ALKS
alkermes plc
26.4 %
IOVA
iovance biotherapeutics inc
24.6 %
RPRX
royalty pharma plc
22.5 %
Top 5 Winners ($)$
dianthus therapeutics inc
3.8 M
GILD
gilead sciences inc
2.4 M
RPRX
royalty pharma plc
2.1 M
MLTX
moonlake immunotherapeutics
1.6 M
JAZZ
jazz pharmaceuticals plc
1.4 M
Top 5 Losers (%)%
ATEC
alphatec hldgs inc
-37.5 %
DOCS
doximity inc
-35.4 %
BSX
boston scientific corp
-30.5 %
OCUL
ocular therapeutix inc
-28.8 %
structure therapeutics inc
-28.7 %
Top 5 Losers ($)$
BSX
boston scientific corp
-17.2 M
LLY
lilly eli & co
-5.9 M
DOCS
doximity inc
-5.8 M
ISRG
intuitive surgical inc
-4.5 M
PRCT
procept biorobotics corp
-3.5 M

Rhenman & Partners Asset Management AB Holdings Map

This heatmap illustrates the top 50 positions within the fund's portfolio.

Current Stock Holdings of Rhenman & Partners Asset Management AB

Rhenman & Partners Asset Management AB has 86 stocks in it's portfolio. About 32% of the portfolio is in top 10 stocks. BSX proved to be the most loss making stock for the portfolio. was the most profitable stock for Rhenman & Partners Asset Management AB last quarter.

$810.49MTotal Value
105Positions
14 May, 2026Last Reported
Current holdings of Current Stock Holdings of Rhenman & Partners Asset Management AB, last reported on 14 May, 2026. Select a row with a linked ticker to view its historical trend.
ExpandHoldingsorted ascending% PortfolioShares Held$ Value% Change
ASND
Ascendis Pharma A/S

Ascendis Pharma A/S

ASND
Rhenman & Partners Asset Management AB's holding in Ascendis Pharma A/S over time
0.42%15,000
$3.43M
0.42%
unchanged 0 percentunchanged